TAK-700
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
SummaryBackground: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC…
Orteronel (TAK-700) is a novel and selective inhibitor of CYP17A1, which is expressed in testicular, adrenal and prostate tumor…
Purpose: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity…
5008 Background: Orteronel, an investigational, non-steroidal, selective 17,20-lyase inhibitor, demonstrated improved…
5042 Background: Orteronel is an investigational, nonsteroidal, selective 17,20-lyase inhibitor. ELM-PC 5 (NCT01193257) did not…
Orteronel (TAK-700), a selective oral nonsteroidal inhibitor of 17 alpha-monooxygenase (17, 20 lyase), blocks androgen synthesis…
A highly sensitive, specific and enantioselective assay has been developed and validated for the estimation of TAK-700…
98 Background: The investigational agent orteronel (TAK-700) is a selective 17,20 lyase inhibitor that down regulates androgenic…
The last several years have seen extraordinary progress in the management of patients with castration resistant prostate cancer…
TPS184 Background: The investigational agent TAK-700 is a selective inhibitor of 17,20-lyase, a key intermediary in adrenal…